Industry News
Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in…
Read More
-Topline Data expected in the last week of July- Excerpt from the Press Release: SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced data…
Read More
Royal Academy of Engineering MacRobert award-winner could transform lives of kidney disease patients, say experts Excerpt from the Press Release: A home dialysis machine inspired by technology used in fruit juice dispensers has won the UK’s most prestigious engineering prize. The device, made by Quanta, is currently used by about 50 patients in the UK,…
Read More
— Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma — — First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sapanisertib in combination with telaglenastat in patients with non-small cell lung cancer — Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 13,…
Read More Findings from a large, multi-cohort study suggest the genomic test can improve care for lung nodule patients with inconclusive bronchoscopy results Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jul. 13, 2022– Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in PLOS ONE show that the company’s Percepta Genomic Sequencing Classifier (GSC) is highly accurate in…
Read More
New synthetic controls add to growing portfolio of NGS applications for viral diseases Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched two human monkeypox virus synthetic DNA controls1. Positive controls provide quality…
Read More
Quantitative biomarkers of demyelination can improve clinical trial design and accelerate development of disease-modifying therapeutics Excerpt from the Press Release: SAN FRANCISCO, July 14, 2022 /PRNewswire/ — Rune Labs, a precision neurology software and data platform company, today announced it is enrolling patients with multiple sclerosis (MS) in a study to identify neurophysiological biomarkers of the disease. The…
Read More
In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one Patients treated with Vabysmo received a median number of 10 injections over the two years versus 15 injections for those treated with aflibercept, potentially decreasing the…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in Brazil for the treatment of sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older who…
Read More
Excerpt from the Press Release: FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the enrollment progress in the Phase II Part II clinical study of the Company’s ADHD medicine (ABV-1505). Since results on the…
Read More